SingerS., DemetriG.D., BaldiniE.H., eFletcherC.D.: Management of soft-tissue sarcoma: an overview and update.Lancet Oncol,1: 75–85, 2000.
2.
SavageD.G., AntmanK.H.: Imatinib mesylate - a new oral target therapy.N Engl J Med,346: 683–693, 2002.
3.
MerchantM.S., WooC.W., MackallC.L., ThieleC.J.: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity.J Natl Cancer Inst,94: 1673–1679, 2002.
4.
WangW.L., HealyM.E., SattlerM., VermaS., LinJ., MaulikG., StilesC.D., GriffinJ.D., JohnsonB.E., SalgiaR.: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571.Oncogene,19: 3521–3528, 2000.
5.
VerweijJ., van OosteromA., BlayJ.Y., JudsonI., RodenhuisS., van der GraafW., RadfordJ., Le CesneA., HogendoornP.C., di PaolaE.D., BrownM., NielsenO.S.: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.Eur J Cancer,39: 2006–2011, 2003.
6.
HotfilderM., LanversC., JurgensH., BoosJ., VormoorJ.: C-kit-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).Cancer Chemother Pharmacol,50: 167–169, 2002.
